BioDrugs

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Certolizumab Pegol in Crohn’s Disease
BioDrugs - Tập 21 - Trang 202-202 - 2012
Trevor A. Winter
Immunopathogenesis and Treatment of Halothane Hepatitis
BioDrugs - Tập 3 - Trang 108-124 - 2012
J. Gerald Kenna, James M. Neuberger
Halothane hepatitis is a very rare but clinically important adverse drug reaction that may cause fatal liver failure. The liver damage appears to arise as a consequence of immune responses to novel hepatic protein antigens that are produced via cytochrome P450-mediated bioactivation of halothane to CF3COCl. This reactive metabolite binds covalently to hepatic proteins, apparently via ε-amino group...... hiện toàn bộ
Expression Systems for the Production of Recombinant Pharmaceuticals
BioDrugs - Tập 18 - Trang 51-62 - 2012
Régis Sodoyer
The new generation of biological products are largely the result of genetic engineering. The qualitative and quantitative demand for recombinant proteins is steadily increasing. Molecular biologists are constantly challenged by the need to improve and optimise the existing expression systems, and also develop novel approaches to face the demands of producing the complex proteins of tomorrow. This ...... hiện toàn bộ
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
BioDrugs - Tập 34 - Trang 713-721 - 2020
Ahmed Almradi, Jurij Hanzel, Rocio Sedano, Claire E. Parker, Brian G. Feagan, Christopher Ma, Vipul Jairath
The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn’s disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation. Many pathways driving inflammation have been described, and different pathway...... hiện toàn bộ
Cyclosporin as Baseline Immunosuppression in Solid Organ Transplantation
BioDrugs - Tập 14 Số 3 - Trang 185-193 - 2000
Michael Winkler
Progress Towards Optimal Trial End-Points in Rheumatoid Arthritis
BioDrugs - Tập 7 - Trang 40-50 - 2012
Maarten Boers, Peter Tugwell, Peter M. Brooks
Trials in rheumatoid arthritis have been difficult to perform and interpret due to disagreement over what to measure. This paper reviews the most frequently used measures and their validity against the background of the Outcome Measures in Rheumatology (OMERACT) consensus conferences. These conferences have resulted in the adoption of a core set of end-points to be used as a minimum in all clinica...... hiện toàn bộ
Felty’s Syndrome
BioDrugs - Tập 7 - Trang 356-365 - 2012
John S. Pixley, Gary M. Patchin
Felty’s syndrome is a complication of rheumatoid arthritis whereby patients develop neutropenia of varying severity. Although the main clinical concern is the development of serious infections, often patients remain asymptomatic or continue with clinical problems related to the rheumatoid arthritis and not to the neutropenia. There is now considerable clinical experience with the use of the recomb...... hiện toàn bộ
Apport du Néoral® en transplantation rénale
BioDrugs - Tập 8 Số Supplement 1 - Trang 12-14 - 1997
Paul Keown
Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: Drug Repurposing Strategy
BioDrugs - Tập 30 - Trang 593-605 - 2016
Balasundaram Preethi, Veerappapillai Shanthi, Karuppasamy Ramanathan
Salmonella typhimurium is the main cause of gastrointestinal illness in humans, and treatment options are decreasing because drug-resistant strains have emerged. The objective of this study was to use computational drug repurposing to identify a novel candidate with an effective mechanism of action to circumvent the drug resistance. We used the Mantra 2.0 database to in...... hiện toàn bộ
Tổng số: 1,190   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 10